Crinetics changes Jeff Knight's title from COO to Chief Development and Operating Officer

Crinetics Pharmaceuticals, Inc.

Title change effective January 2, 2026; responsibilities expanded.
No change to Jeff Knight's compensation arrangements.
No arrangements or family relationships with other executives or directors.
Business experience described in prior proxy statement remains unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.